DURHAM, N.C., Nov. 19 /PRNewswire/ -- Regado Biosciences today announced Doug Gooding, Regado's Chief Executive Officer, will present at the 19th Annual Piper Jaffray Health Care Conference at the Pierre Hotel in New York City on November 27, 2007, at 3:50 PM Eastern Time.
About Regado Biosciences
Regado Biosciences is pioneering a new therapeutic field with the discovery and development of drug:antidote systems. Regado's drug:antidote systems are designed to give physicians the ability to fine-tune the therapeutic effect desired for each patient and in each setting. A spin-out of the Department of Surgery at Duke University Medical Center, Regado was created to answer the therapeutic needs identified by its scientific founders.
The Company's proprietary platform technology enables the discovery of oligonucleotide-based drug-antidote pairs to any target protein. Regado initially is focusing its discovery and development efforts on the acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles. Potential future indications for Regado's technology include acute coronary syndromes and other coronary revascularization procedures that would benefit from the availability of an antidote-reversible agent.
|SOURCE Regado Biosciences|
Copyright©2007 PR Newswire.
All rights reserved